These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249 [TBL] [Abstract][Full Text] [Related]
26. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target. Kundu D; Selvaraj C; Singh SK; Dubey VK J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243 [TBL] [Abstract][Full Text] [Related]
27. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease. Wang Y; Gao Q; Yao P; Yao Q; Zhang J J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210 [TBL] [Abstract][Full Text] [Related]
28. Potential of NO donor furoxan as SARS-CoV-2 main protease (M Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550 [TBL] [Abstract][Full Text] [Related]
29. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach. Fadaka AO; Aruleba RT; Sibuyi NRS; Klein A; Madiehe AM; Meyer M J Biomol Struct Dyn; 2022 May; 40(8):3416-3427. PubMed ID: 33200673 [TBL] [Abstract][Full Text] [Related]
32. Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations. Singh R; Bhardwaj VK; Das P; Bhattacherjee D; Zyryanov GV; Purohit R Comput Biol Med; 2022 Jul; 146():105572. PubMed ID: 35551011 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613 [TBL] [Abstract][Full Text] [Related]
34. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M Elseginy SA J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801 [TBL] [Abstract][Full Text] [Related]
35. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease. Kar P; Lipowsky R; Knecht V J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718 [TBL] [Abstract][Full Text] [Related]
36. Leucoefdin a potential inhibitor against SARS CoV-2 M Singh A; Mishra A J Biomol Struct Dyn; 2021 Aug; 39(12):4427-4432. PubMed ID: 34281489 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies. Abdizadeh R; Hadizadeh F; Abdizadeh T J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354 [TBL] [Abstract][Full Text] [Related]